Erratum: Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine (Journal of Clinical Investigation (2012) 122, 2, (654-673) DOI:10.1172/JCI60556);Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine

Journal of Clinical Investigation

Volumn 122, Issue 2, 2012, Pages 654-673

  Jing, Lichen ^a   Haas, Jürgen ^b,c   Chong, Tiana M ^a   Bruckner, Joseph J ^a   Dann, Greg C ^a   Dong, Lichun ^a   Marshak, Joshua O ^a   McClurkan, Christopher L ^a   Yamamoto, Tori N ^d   Bailer, Susanne M ^b   Laing, Kerry J ^a   Wald, Anna ^a,d   Verjans, Georges M G M ^e   Koelle, David M ^a,d,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Fred Hutchinson Cancer Research Center   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; HERPES SIMPLEX VACCINE; PROTEOME; T LYMPHOCYTE ANTIGEN;

ADULT; ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; FEMALE; GENETIC ASSOCIATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; VACCINIA VIRUS;

EID: 84863011888     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65722     Document Type: Erratum

References (93)

1. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, Pennsylvania, USA: Lippincott, Williams, and Wilkins; 2007:2501-2602.
2. Stanberry LR, et al. Prophylactic vaccination against genital herpes with adjuvanted recombinant glycoprotein D vaccine: two randomized contolled trials. N Engl J Med. 2002;347(21):1652-1661.
3. Verjans GMGM, et al. Selective retention of herpes simplex virus specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A. 2007;104(9):3496-3501. (Pubitemid 46364187)
4. Lichen J, et al. Tegument- and glycoprotein-reactive HSV-1-specific CD4 and CD8 T cells localize to human trigeminal ganglia [abstract]. J Immunol. 2009;182:128.24.
5. Prabhakaran K, et al. Sensory neurons regulate the effector functions of CD8+ T cells in controlling HSV-1 latency ex vivo. Immunity. 2005;23(5):515-525. (Pubitemid 41587891)
6. Zhu J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204(3):595-603. (Pubitemid 46457082)
7. Zhu J, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15(8):886-892.
8. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nocnlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524-530.
9. Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol. 1998;72(8):6888-6892. (Pubitemid 28324011)
10. Sawtell NM, Thompson RL, Stanberry LR, Bernstein DI. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis. 2001;184(8):964-971. (Pubitemid 32955112)
11. Orr MT, Orgun NN, Wilson CB, Way SS. Cutting Edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol. 2007;178(8):4731-4735. (Pubitemid 46595253)
12. Iijima N, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med. 2008;205(13):3041-3052.
13. Schacker T, Zeh J, Hu H-L, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis. 1998;178(6):1616-1622. (Pubitemid 28558132)
14. McGeoch DJ, Dolan A, Donald S, Brauer DH. Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. Nucleic Acids Res. 1986;14(4):1727-1745.
15. McGeoch DJ, et al. The complete DNA sequence of the long unique region of herpes simplex virus type 1. J Gen Virol. 1988;69(pt 7):1531-1574.
16. Chentoufi AA, et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol. 2008;180(1):426-437.
17. Chentoufi AA, et al. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol. 2010;184(5):2561-2571.
18. Koelle DM, et al. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. J Virol. 2000;74(23):10930-10938. (Pubitemid 32223957)
19. Verjans GMGM, et al. Identification and characterization of herpes simplex virus-specific CD4+ T cells in corneas of herpetic stromal keratitis patients. J Infect Dis. 1998;177(2):484-488.
20. Verjans GMGM, Remeijer L, Mooy CM, Osterhaus ADME. Herpes simplex virus specific T-cells infiltrate the cornea of patients with herpes stromal keratitis: no evidence for intra-corneal autoreactive T-cells in human HSK. Invest Ophthalmol Vis Sci. 2000;41(9):2607-2612. (Pubitemid 30624389)
21. Remeijer L, Osterhaus A, Verjans G. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm. 2004;12(4):255-285. (Pubitemid 40138184)
22. Verjans GM, et al. Intraocular T cells of patients with herpes simplex (HSV)-induced acute retinal necrosis recognize HSV tegument proteins VP11/12 and VP13/14. J Infect Dis. 2000;182(3):923-927.
23. Verjans GM, et al. T cells specific for the triggering virus infiltrate the eye in patients with herpes simplex virus-mediated acute retinal necrosis. J Infect Dis. 1998;178(1):27-34. (Pubitemid 28328072)
24. Yasukawa M, Zarling JM. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. III. Analysis of viral glycoproteins recognized by CTL clones by using recombinant herpes simplex viruses. J Immunol. 1985;134(4):2679-2687.
25. Hoshino Y, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2005;79(1):410-418. (Pubitemid 39648394)
26. de Bruyn G, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2006;24(7):914-920.
27. Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine. 1999;17(15-16):1951-1963. (Pubitemid 29172365)
28. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC. A cytosolic herpes simplex protein inhibits antigen presentation to CD8+ T lymphocytes. Cell. 1994;77(4):525-535.
29. Hill A, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995;375(6530):411-415.
30. Tigges MA, Leng S, Johnson DC, Burke RL. Human herpes simplex (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol. 1996;156(10):3901-3910.
31. Posavad CM, Newton JJ, Rosenthal KL. Inhibition of human CTL-mediated lysis by fibroblasts infected with herpes simplex virus. J Immunol. 1993;151(9):4865-4873. (Pubitemid 23318540)
32. Sloan DD, et al. Inhibition of TCR signaling by herpes simplex virus. J Immunol. 2006;176(3):1825-1833. (Pubitemid 43134327)
33. Jirmo AC, Nagel CH, Bohnen C, Sodeik B, Behrens GM. Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1. J Immunol. 2009;182(1):283-292.
34. Smith CM, et al. Cutting Edge: Conventional CD8alpha(+) dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol. 2003;170(9):4437-4440. (Pubitemid 36519947)
35. Allan RS, et al. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science. 2003;301(5641):1925-1928. (Pubitemid 37229056)
36. Allan RS, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity. 2006;25(1):153-162. (Pubitemid 44066832)
37. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science. 2008;319(5860):198-202.
38. Bedoui S, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10(5):488-495.
39. Bosnjak L, Miranda-Saksena M, Koelle DM, Boadle RA, Jones CA, Cunningham AL. Herpes simplex virus infection of human dendritic cells induces apoptosis and allows cross-presentation via uninfected dendritic cells. J Immunol. 2005;174(4):2220-2227. (Pubitemid 40223968)
40. Wolfl M, Kuball J, Eyrich M, Schlegel PG, Greenberg PD. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73(11):1043-1049.
41. Wehler TC, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods. 2008;339(1):23-37.
42. Watanabe K, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol. 2008;88(3):311-320.
43. Corey L, et al. Two double-blind, placebo-controlled trials of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition. JAMA. 1999;282(4):331-340.
44. Straus SE, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994;343(8911):1460-1463. (Pubitemid 24176334)
45. Straus SE, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins B and D: results of a placebo-controlled vaccine trial. J Infect Dis. 1997;176(5):1129-1134. (Pubitemid 27460974)
46. Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol. 2000;74(23):11422-11425. (Pubitemid 32224015)
47. Jing L, et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T cell profiling. J Virol. 2008;82(14):7120-7134. (Pubitemid 351977730)
48. Sylwester AW, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673-685. (Pubitemid 41248418)
49. Saulquin X, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirs by bulk screening. Eur J Immunol. 2000;30(9):2531-2539.
50. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
51. Loret S, Guay G, Lippe R. Comprehensive characterization of extracellular herpes simplex virus type 1 virions. J Virol. 2008;82(17):8605-8618.
52. Koelle DM, et al. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A. 2003;100(22):12899-12904. (Pubitemid 37339997)
53. Koelle DM, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin Vaccine Immunol. 2008;15(5):773-782. (Pubitemid 351967022)
54. Laing KJ, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol. 2010;30(5):703-722.
55. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med. 2008;59:381-395. (Pubitemid 351287944)
56. Koelle DM, Chen HB, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol. 2001;166(6):4049-4058. (Pubitemid 32224935)
57. Dong L, Li P, Oenema T, McClurkan CL, Koelle DM. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J Immunol. 2010;184(6):3063-3071.
58. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest. 1985;75(1):226-233. (Pubitemid 15171242)
59. Dufour F, Sasseville AM, Chabaud S, Massie B, Siegel RM, Langelier Y. The ribonucleotide reductase R1 subunits of herpes simplex virus types 1 and 2 protect cells against TNFalpha- and FasL-induced apoptosis by interacting with caspase-8. Apoptosis. 2011;16(3):256-271.
60. St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL. Defining the herpes simplex virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol. 2011;186(7):3927-3933.
61. Tomazin R, et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol. 1998;72(3):2560-2563. (Pubitemid 28100825)
62. Tigges MA, Koelle DM, Hartog K, Sekulovich RE, Corey L, Burke RL. Human CD8+ herpes simplex virus-specific cytotoxic T lymphocyte clones recognize diverse virion protein antigens. J Virol. 1992;66(3):1622-1634.
63. Puttur FK, et al. Herpes simplex virus infects skin gamma delta T cells before Langerhans cells and impedes migration of infected Langerhans cells by inducing apoptosis and blocking E-cadherin downregulation. J Immunol. 2010;185(1):477-487.
64. Jin H, Yan Z, Ma Y, Cao Y, He B. A herpesvirus virulence factor inhibits dendritic cell maturation through protein phosphatase 1 and Ikappa B kinase. J Virol. 2011;85(7):3397-3407.
65. Salio M, Cella M, Suter M, Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur J Immunol. 1999;29(10):3245-3253. (Pubitemid 29484215)
66. Akatsuka Y, et al. Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens. 2002;59(6):502-511. (Pubitemid 35034470)
67. Koelle DM, et al. Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest. 2002;110(4):537-548. (Pubitemid 34919708)
68. Posavad CM, Wald A, Hosken N, Huang M-L, Koelle DM, Corey L. T cell immunity to herpes simplex virus in seronegative persons: silent infection or acquired immunity. J Immunol. 2003;170(8):4380-4388. (Pubitemid 36428208)
69. Zaunders JJ, et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol. 2009;183(4):2827-2836.
70. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26(4):662-667. (Pubitemid 18087189)
71. Jing L, Chong TM, McClurkan CL, Huang J, Story BT, Koelle DM. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol. 2005;175(11):7550-7559. (Pubitemid 41713454)
72. Koelle DM, et al. Antigenic specificity of human CD4+ T cell clones recovered from recurrent genital HSV-2 lesions. J Virol. 1994;68(5):2803-2810. (Pubitemid 24129727)
73. Marsh SG, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455.
74. Spruance SL, Chow FS. Pathogenesis of herpes simplex virus in cultures of epidermal cells from subjects with frequent recurrences. J Infect Dis. 1980;142(5):671-675. (Pubitemid 11138418)
75. Kit S, Kit M, Qavi H, Trkula D, Otsuka H. Nucleotide sequence of the herpes simplex virus type 2 (HSV-2) thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide and its comparison with the HSV-1 thymidine kinase gene. Biochim Biophys Acta. 1983;741(2):158-170. (Pubitemid 14201808)
76. Jing L, Chong TM, McClurkan CL, Huang J, Story BT, Koelle DM. Diversity in the acute CD8 T cell response to vaccinia virus in humans [published correction appears in J. Immunol. 2007;179(4):2659]. J Immunol. 2005;175(11):7550-7559. (Pubitemid 41713454)
77. Jing L, et al. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol. 2007;178(10):6374-6386. (Pubitemid 46717422)
78. Yasukawa M, Zarling JM. Autologous herpes simplex virus-infected cells are lysed by human natural killer cells. J Immunol. 1983;131(4):2011-2016. (Pubitemid 13007854)
79. Koelle DM, Chen H, Gavin MA, Wald A, Kwok WW, Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol. 2001;166(6):4049-4058. (Pubitemid 32224935)
80. Quakkelaar ED, et al. Enhanced expression of HIV antigens and improved cross-presentation by replication competent recombinant vaccinia virus vector. PLoS ONE. 2011;6(2):e16819.
81. Koelle DM. Expression cloning for the discovery of viral antigens and epitopes recognized by T-cells. Methods. 2003;29(3):213-226. (Pubitemid 36513438)
82. Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol. 1998;72(9):7476-7483. (Pubitemid 28377879)
83. Kask AS, et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine. 2010;28(47):7483-7491.
84. Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood. 2002;99(10):3844-3847. (Pubitemid 34534560)
85. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SG. IMGT/HLA database-a sequence database for the human histocompatibility complex. Tissue Antigens. 2000;55(3):280-287. (Pubitemid 30150951)
86. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol. 1980;1(2):121-129. (Pubitemid 12238821)
87. Jing L, et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol. 2008;82(14):7120-7134. (Pubitemid 351977730)
88. Jing L, et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods. 2009;347(1-2):36-45.
89. Eyles JE, et al. Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics. 2007;7(13):2172-2183. (Pubitemid 47067203)
90. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest. 1998;101(7):1500-1508. (Pubitemid 28166848)
91. Vita R, et al. The immune epitope database 2.0. Nucleic Acids Res. 2010;38(Database issue):D854-D862.
92. Marsh SGE, Parham P, Barber LD. The HLA FactsBook. San Diego, California, USA: Academic Press; 2000.
93. Koelle DM, et al. Expression of cutaneous lymphocyte-associated antigen by CD8+ T-cells specific for a skin-tropic virus. J Clin Invest. 2002;110(4):537-548. (Pubitemid 34919708)